FindTrial
Sign In

Expression and correlation analysis of UBE2C and CDC20 in ovarian cancer

Expression and correlation analysis of UBE2C and CDC20 in ovarian cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200064969
Enrollment
Unknown
Registered
2022-10-24
Start date
2022-10-25
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

group 1:None
group 2:None
group 3:None
group 4:None

Sponsors

Affiliated Hospital of North Sichuan Medical College
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Pathologically confirmed ovarian serous carcinoma specimens; 2. Ovarian serous carcinoma cases were all primary, and no radiotherapy, chemotherapy or hormone therapy was performed before operation; 3. The normal ovarian tissue was obtained from patients who had undergone double annexectomy due to hysteromyoma.

Exclusion criteria

Exclusion criteria: 1. Combined with other malignant tumors; 2. Participating in other research; 3. The patient's clinical information is incomplete.

Design outcomes

Primary

MeasureTime frame
CDC20;UBE2C;—

Countries

China

Contacts

Public ContactJun Liu

Affiliated Hospital of North Sichuan Medical College

236646471@qq.com+86 15983775502

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026